NF-κB and the Innate Immune Response in the Respiratory Distress Syndrome of the Newborn: Commentary on the article by Cheah et al. on page 616

Pediatric Research

Volumn 57, Issue 5, 2005, Pages 613-615

  Chatila, Talal A ^a   Smith, Jeffery B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; DEXAMETHASONE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; SURFACTANT; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ARTIFICIAL VENTILATION; ASSISTED VENTILATION; CELL COUNT; CELL STIMULATION; CHORIOAMNIONITIS; CYTOKINE PRODUCTION; GENE ACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HYALINE MEMBRANE DISEASE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; INFLAMMATORY CELL; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LUNG ALVEOLUS EPITHELIUM; LUNG DYSPLASIA; LUNG FUNCTION; MONOCYTE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEUTROPHIL; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PREMATURITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TREATMENT OUTCOME; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; NEWBORN; PHYSIOLOGY;

CYTOKINES; HUMANS; IMMUNE SYSTEM; INFANT, NEWBORN; INFLAMMATION; NF-KAPPA B; PROTEIN BINDING; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SURFACE-ACTIVE AGENTS;

EID: 17744363269     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1203/01.PDR.0000161703.33428.91     Document Type: Editorial

References (21)

1. Hansen TN, Hawgood S 2004 Hayline membrane disease. In: Rudolph CD, Rudolph AM, Hostetter MK, Lister GE, Siegel NJ (eds) Rudolph’s Pediatrics. McGraw-Hill, New York, pp 127-135
2. Jobe AH, Bancalari E 2001 Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163:1723-1729
3. Speer CP 2003 Inflammation and bronchopulmonary dysplasia. Semin Neonatol 8:29-38
4. Cheah F-C, Winterbourn CC, Darlow BA, Mocatta TJ, Vissers MCM 2005 Nuclear Factor κB Activation in Pulmonary Leukocytes from Infants with Hyaline Membrane Disease: Associations with Chorioamnionitis and Ureaplasma urealyticum Colonization. Pediatr Res 57:616
5. Hayden MS, Ghosh S 2004 Signaling to NF-kappaB. Genes Dev 18:2195-2224
6. Takeda K, Kaisho T, Akira S 2003 Toll-like receptors. Annu Rev Immunol 21:335-376
7. Lee PJ, Choi AM 2003 Pathways of cell signaling in hyperoxia. Free Radic Biol Med 35:341-350
8. Ambalavanan N, Carlo WA 2004 Bronchopulmonary dysplasia: new insights. Clin Perinatol 31:613-628
9. Droemann D, Goldmann T, Branscheid D, Clark R, Dalhoff K, Zabel P, Vollmer E 2003 Toll-like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 119:103-108
10. Guillot L, Medjane S, Le-Barillec K, Balloy V, Danel C, Chignard M, Si-Tahar M 2004 Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem 279:2712-2718
11. Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, Ganz T, Randell SH, Modlin RL 2003 Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J Immunol 171:6820-6826
12. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, Millar AB 2004 Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol 31:241-245
13. Li Y, Zhang W, Mantell LL, Kazzaz JA, Fein AM, Horowitz S 1997 Nuclear factor-kappaB is activated by hyperoxia but does not protect from cell death. J Biol Chem 272:20646-20649
14. Yang G, Abate A, George AG, Weng YH, Dennery PA 2004 Maturational differences in lung NF-kappaB activation and their role in tolerance to hyperoxia. J Clin Invest 114:669-678
15. Skerrett SJ, Liggitt HD, Hajjar AM, Ernst RK, Miller SI, Wilson CB 2004 Respiratory epithelial cells regulate lung inflammation in response to inhaled endotoxin. Am J Physiol Lung Cell Mol Physiol 287:L143-L152
16. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M 1995 Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290
17. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr 1995 Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270:283-286
18. Reichardt HM, Tuckermann JP, Gottlicher M, Vujic M, Weih F, Angel P, Herrlich P, Schutz G 2001 Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J 20:7168-7173
19. Committee on Fetus and Newborn 2002 Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 109:330-338
20. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, Tsai CH 2004 Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350:1304-1313
21. Jobe AH 2004 Postnatal corticosteroids for preterm infants-do what we say, not what we do. N Engl J Med 350:1349-1351